Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis;Estudo comparativo entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 41, Issue 4, 2008, Pages 424-427

  Da Costa Filho, Arnoldo Velloso ^a   Lucas, Íris Campos ^a   Sampaio, Raimunda Nonata Ribeiro ^a,b  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b SHIS QI 25 ^*  (Brazil)

Author keywords

Cutaneous leishmaniasis; Miltefosine; Therapy

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

ANIMAL EXPERIMENT; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG EFFICACY; LEISHMANIA; LEISHMANIASIS; MOUSE; NONHUMAN; TREATMENT OUTCOME;

ANIMALS; ANTIPROTOZOAL AGENTS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MICE; MICE, INBRED C57BL; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE;

LEISHMANIA AMAZONENSIS; MUS;

EID: 56049083070     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822008000400022     Document Type: Article

References (22)

1. Aebischer T. Recurrent Cutaneous leishmaniasis: a role for persistent parasites? Parasitology Today 10: 25-28, 1994.
2. Belliard AM, Leroy C, Banide H, Farinotti R, Lacour B. Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis. Experimental Parasitology 103: 51-56, 2003.
3. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochemical Pharmacology 36: 2633-2636, 1987.
4. Guevara P, Rojas E, Gonzalez N, Scorza V, Añez N, Valera M. Presence of Leishmania braziliensis in Blood Samples from Cured Patients or at Different Stages of Immunotherapy. Clinical Diagnosis Laboratory Immunology 1: 385-389, 1994.
5. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrobial Agents Chemotherapy 36: 1630-1634, 1992.
6. Lima HC, Bleyenberg JA, Titus RG. A Simple Method for Quantifying Leishmania in Tissues of Infected Animals. Parasitology Today 13:80-82, 1997.
7. Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, Razaghian A R, Kabir M J, Nadim A. comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis ( ZCL) by a randomized clinical trial in Iran. Acta Tropica 103: 33-40, 2007
8. More B, Bhatt H, Kukreja V, Ainapure S. Miltefosine: great expectations against visceral leishmaniasis. Journal Postgraduate Medical 49: 101-103, 2003.
9. Murray H. Supression of postreatment recurrence of experimental visceral Leishmaniasis in t-cell-deficient mice by oral miltefosine. Antimicrobial Agents Chemotherapy 44: 3235-3236, 2000.
10. Murray H, Delph-Etiene S. Visceral leishmanicidal activity for hexadecylphosphocoline in mice deficient in T Cells and activates macrophage microbicidas mechanisms. American Journal of Infectious Disease 181: 795-799, 2000.
11. Paris C, Loiseau PM, Bories C, Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrobial Agents and Chemotherapy 48: 852-859, 2004
12. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biological Disease 2: 14, 2003.
13. Prassad R, Kumar R, Jaiswal P, Singh K. Miltefosine: an oral drug for visceral leishmaniasis. Indian Journal Pediatry 71: 143-144, 2004.
14. Sampaio RNR, Marsden PD, Furtado T, Sampaio JHD. Avaliação do tratamento da leishmaniose cutâneo-mucosa com três esquemas diferentes de antimoniais pentavalentes. Anais Brasileiros de Dermatologia 64: 201-205, 1989.
15. Sampaio RNR, Sampaio JHD, Marsden PD. Pentavalent atimonial treatment in mucosal leishmaniasis. Lancet 1: 1097, 1985.
16. Schimdt-Ott R, Klenner T, Overath P, Aebischer T. Topical treatment with hexadecylphosphocoline efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 93: 85-90, 1999.
17. Schubach A, Haddad F, Oliveira-Neto MP, Degrave W, Pirmez C, Grimaldi JG, Fernandes O. Detection of Leishmania DNA by the polymerase chain reaction in scars of treated human cases. Journal of Infectious Diseases 178: 911-914, 1998.
18. Seiferd K, Croft L. In vitro and in vivo interations between miltefosine and other antileishmanial drugs. Antimicrobial Agents Chemotherapy 50: 73-79, 2006.
19. Sindermann H, Croft L, Engel KR, Bommer W, Eibl J, Unger C, Engel J. Miltefosine (Impavido®): the first oral treatment against leishmaniasis. Medical Microbiology Immunology 193: 173-180, 2004.
20. Sindermann H, Engel KR, Fischer C, Bommer W. Miltefosine Compassionate use Program. Oral miltefosine for leishmaniasis in immunocompromissed patients: compassionate use in 39 patients with HIV infection. Clinical Infectious Diseases 39: 1520-1523, 2004.
21. Soto J, Toledo JT. Oral miltefosine to treat new world cutaneous leishmaniasis. Lancet Infectious Diseases 7: 7-7, 2007.
22. Verma K, Dey C. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrobial Agents Chemotherapy 48: 3010-3015, 2004.